Log in or register to see all Alerts
New HTA Decisions in Scotland
June 2020
Drug name
IMBRUVICA® (ibrutinib)
Company
Janssen-Cilag Ltd
Decision date
11/11/2019
Therapeutic area
Cancer
Therapeutic sub area
Blood and bone marrow cancers
Decision
Not recommended
Indication
In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.
Decision Detail
In the absence of a submission from the holder of the marketing authorisation, ibrutinib (Imbruvica®) is not recommended for use within NHS Scotland.
Summary
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result the SMC cannot recommend its use within NHS Scotland.